PhRMA Prepares For More TRIPS Import Talks; U.S. Lays Out “Interim Plan”
Executive Summary
The Pharmaceutical Research & Manufacturers of America expects TRIPS negotiations on the importation of drugs made under compulsory license to resume within several weeks
You may also be interested in...
WTO Rx Compulsory Licensing Agreement Solves “Symbolic” Issue, USTR Says
World Trade Organization final agreement on drug compulsory licensing represents progress on a "symbolic" issue, Assistant U.S. Trade Representative for Services, Investment and Intellectual Property James Mendenhall said Sept. 2 at an American Enterprise Institute forum on the Trade-Related Aspects of Intellectual Property Rights agreement
WTO Rx Compulsory Licensing Agreement Solves “Symbolic” Issue, USTR Says
World Trade Organization final agreement on drug compulsory licensing represents progress on a "symbolic" issue, Assistant U.S. Trade Representative for Services, Investment and Intellectual Property James Mendenhall said Sept. 2 at an American Enterprise Institute forum on the Trade-Related Aspects of Intellectual Property Rights agreement
Pfizer CEO Sees “Emerging Consensus” On Global Patent Protection Issues
There is an "emerging consensus" that the best approach to providing antiretroviral drug therapies to developing countries includes strong intellectual property rules, which then make product donations possible, Pfizer CEO Hank McKinnell, PhD, said